Depo-Medroxyprogesterone Acetate (DMPA, Depo-Provera) Use With Certain Anti-HIV Drugs in HIV-Infected Women

Exclusion Criteria

• •Patients will not be eligible for this study if they:
• •Have taken anti-HIV drugs within 30 days before study entry but have chosen not to take them.
• •Are taking only 1 NRTI.
• •Are taking anti-HIV drugs other than those listed in the treatment groups, including tenofovir, amprenavir, and lopinavir/ritonavir, or have taken tenofovir, amprenavir, or lopinavir/ritonavir within 30 days before study entry.
• •Have taken ZDV and d4T together within 30 days before study entry.
• •Are not able to take the anti-HIV drugs properly while on the study, in the opinion of the investigator.
• •Are allergic to DMPA, MPA, or any of the other ingredients in DMPA.
• •Have received DMPA within 180 days before study entry.
• •Have received other hormones (Provera, oral contraceptives, hormonal replacement therapy, or anabolic drugs \[e.g., nandrolone decanoate, megestrol acetate\]) within 30 days before study entry.
• •Are taking any of the following: amiodarone, astemizole, bepridil, buspirone, carbamazepine, cimetidine, cisapride, clarithromycin, cyclosporine, dihydroergotamine, diltiazem, ergotamine, erythromycin, flecainide, glucocorticoids, grapefruit juice, St. John's wort, itraconazole, ketoconazole, lovastatin, midazolam, nefazodone, phenobarbital, phenytoin, pimozide, pioglitazone, propafenone, propofol, quinidine, rifabutin, rifampin, rosiglitazone, simvastatin, tacrolimus, terfenadine, ticlopidine, triazolam, or verapamil.
• •Have taken any of the following drugs within 30 days before study entry: amiodarone, astemizole, bepridil, buspirone, carbamazepine, cisapride, clarithromycin, cyclosporine, dihydroergotamine, ergotamine, erythromycin, flecainide, glucocorticoids, St. John's wort, itraconazole, ketoconazole, lovastatin, midazolam, nefazodone, phenobarbital, phenytoin, pimozide, pioglitazone, propafenone, propofol, quinidine, rifabutin, rifampin, rosiglitazone, simvastatin, tacrolimus, terfenadine, ticlopidine, or triazolam.
• •Have started, stopped, or changed doses, within 30 days before study entry, of certain drugs including: benzodiazepines, except midazolam and triazolam; bupropion; calcium channel blockers, except diltiazem and verapamil; fluconazole; lipid-lowering drugs except pravastatin (i.e., atorvastatin, cerivastatin, and fluvastatin, but not lovastatin and simvastatin); isoniazid; mexiletine; zaleplon; and zolpidem. The patient can, however, remain on stable doses of these drugs during the study.
• •Are receiving methadone maintenance treatment for less than 60 days before study entry.
• •Are breast-feeding.
• •Have had a baby within 30 days before study entry.
• •Have had their uterus or both ovaries removed.
• •Abuse drugs or alcohol.
• •Cannot stop drinking alcohol 1 day before and during the testing at entry and at Week 4.
• •Have had a change in smoking habits within 6 weeks before study entry. Patients may have either stopped or started smoking more than 6 weeks before study entry.
• •Have cancer of the reproductive system, vaginal bleeding of unknown cause, thyroid problems, liver tumors, or serious eye problems at any time before study entry.
• •Are taking investigational drugs without approval of the protocol chair.